Grifols Egypt for Plasma Derivatives is a joint venture company between the National Service Projects Organization (NSPO) and Grifols. By combining the expertise, technology and resources of both organizations, this strategic partnership seeks to strengthen Egypt’s healthcare system through achieving self-sufficiency of plasma-derived medicines while reinforcing Grifols’ international expansion in the Middle East and Africa.
The scope of the project entails opening 20 plasma donor centers and establishing all required manufacturing facilities to produce essential medicines. This includes testing and warehousing operations, a protein purification plant and a plasma fractionation plant with a capacity of 1 million liters annually that is expected to double in the future.
Grifols Egypt for Plasma Derivatives strives to be the leading producer and supplier of plasma derivatives in the Middle East and Africa and is committed to applying the highest safety and quality standards in compliance with international regulations.
To enhance the quality of Egypt’s healthcare by securing self-sufficiency in safe, high-quality plasma derivatives and to become the main supplier of these products in the Middle East and Africa.
The National Service Projects Organization (NSPO) was established in Egypt in 1979 to ensure self-sufficiency of the Egyptian Armed Forces demands and to market surplus production both nationally and internationally. The agency is considered one of the leading national institutions supporting the Egyptian economy.
The NSPO is one of the largest companies operating in the production of agricultural fertilizers, industrial gases, solid and liquid alum, chlorine, caustic soda, and different acids, as well as the production of aerosols.
Owning 49 companies in multiple fields, every day the NSPO makes a positive contribution to the Egyptian economy and society.
For more information, please visit nspo.com.eg
Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries.
As pioneers in the field of plasma science, we are one of the largest plasma companies, with a growing network of donation centers worldwide. We develop this plasma into essential medicines used to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, we also offer a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. We continue to advance our legacy of innovation by supplying tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.
Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.
For more information, please visit Grifols.com
Plasma, essential for human life, is the liquid part of blood. Transparent and with a golden tint, it makes up 55% of blood’s total volume and contains critical proteins responsible for important life functions, such as ensuring that the immune system functions correctly and clotting blood.
For patients lacking these proteins, plasma-derived medicines, are often the only possible treatment for many diseases. They include immunoglobulins for primary and secondary immunodeficiencies and autoimmune disorders, coagulation factors for bleeding disorders, and alpha-1 proteinase inhibitors to treat lung and liver disease. Research is also determining the role of plasma therapies to treat emerging infectious diseases such as COVID-19.
Because plasma is a naturally occurring material – it’s in our body – patients depend on the generosity of healthy volunteer donors for plasma-derived therapies. Long production cycles including rigorous quality and safety checks can take up to a year from donation to manufacture a medicine. Large volumes are needed. As many as 1,200 donations are required to treat just one patient with hemophilia, a bleeding disorder, during a year.
Most plasma is obtained through a process known as plasmapheresis, a technique developed by Grifols in 1951 through which plasma is separated from the other blood components, which are then reinfused into the donor.
For more information on plasma proteins and their importance, please visit the Plasma Protein Therapeutics Association (PPTA).
Anyone aged 18 to 60, weighing more than 50 kg and in good health, is eligible for a medical examination and pre-donation tests to confirm eligibility to donate.
It takes around two hours for new donors (time required to undergo a full medical examination and review medical history). Repeated donors can donate in about one hour.
We are glad that you are interested in becoming a plasma donor. It's as safe and easy as donating whole blood, and you are also helping people.
Plasma donation is built on people like you who understand the value of helping others in need. We look forward to helping you make your first donation.
6th October:
El Hosary Square Plot number 2, El-Tahrir Rd 1st
Giza, Egypt
Call us on 15442
Tolip El Narges Hotel
Teseen Street, Fifth Settlement, Cairo
EGYPT
contact@grifolsegyptplasma.com